Precision Genomics’ New mRNA Technology May Be a Solution to Help Diagnose and Establish Treatment for Long Covid

SPARKS, NV / ACCESSWIRE / October 25, 2022 / (OTC PINK:LUDG) Precision Genomics, a wholly owned division of Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers and medical artificial intelligence (AI) to diagnose and manage chronic diseases, is pleased to announce that our new mRNA technology may offer a solution to assist in the diagnosis of and establish treatment protocols for, the current healthcare crisis, Long Covid.

Long Covid (the long-term effects of Covid), or chronic Covid, can include a wide range of ongoing health problems; these conditions can last weeks, months, or longer. Post-COVID conditions are found more often in people with severe COVID-19 illness, but anyone infected with the virus that causes COVID-19 can experience post-COVID conditions, even people with a mild illness or no symptoms from COVID-19 (CDC, September 1, 2022). The CDC states, "There is no test to diagnose post-COVID conditions, and people may have a wide variety of symptoms that could come from other health problems."

A research team led by Drs. Benjamin tenOever at the NYU Grossman School of Medicine and Venetia Zachariou at the Icahn School of Medicine at Mount Sinai set out to understand the underlying biology of Long COVID. The team's preclinical research findings in a hamster model suggest that the molecular mechanism behind many Long COVID-19 symptoms stems from persistent inflammation. Ludwig's management believes that the Company's proprietary, patent-pending, mRNA genomic inflammatory marker technology may be the needed approach to shedding light on Long Covid, a continually evolving and perplexing medical problem with unmet medical needs. In this regard, Ludwig is in the process of establishing formal clinical trials to establish the efficacy of its technology as it relates to Long Covid.

How Ludwig's Technology Could Work

A person requests a Precision Genomics mRNA test kit containing a cotton-tipped swab with easily read instructions on obtaining a sample of cheek cells and returns the completed package to the appropriate Ludwig testing facility. The company's proprietary, patent-pending, 48-gene mRNA microarray captures a snapshot of the person's disease and has the potential to measure the body's response to treatment. Ludwig's planned medical AI program will use deep machine learning to discover hidden gene patterns related to the inflammatory causation of specific diseases.